SRC
CXM

Shufro Rose & Co’s CARDIUM THERAPEUTICS INC NEW CXM Stock Holding History

Shufro Rose & Co’s Portfolio CXM Stock Details CXM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-625
Closed – – 270
2013
Q2 		$0 Buy
+625
New +$1.13K ﹤0.01% 263

Other funds holding CXM

Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Canada Life
Canada Life Winnipeg, Manitoba, Canada $55.8B AUM 26.04% 1-Year Est. Return

Shufro Rose & Co's CXM Position: Q3 2013 in Review

Shufro Rose & Co sold out of CARDIUM THERAPEUTICS INC NEW (CXM) in Q3 2013, closing a stake of 625 shares.

Shufro Rose & Co first reported a position in CXM in Q2 2013 and held it in 1 quarter. The position peaked at $0 in Q2 2013. 8 funds tracked by Wall St. Rank hold CXM as of Q3 2013.

  • Shufro Rose & Co reported no remaining CARDIUM THERAPEUTICS INC NEW position as of Q3 2013 after selling out during the quarter.
  • Shufro Rose & Co sold 625 CARDIUM THERAPEUTICS INC NEW shares in Q3 2013.
  • Shufro Rose & Co first reported a position in CARDIUM THERAPEUTICS INC NEW in Q2 2013 and held it in 1 quarter.
  • Shufro Rose & Co's CARDIUM THERAPEUTICS INC NEW position peaked at $0 in Q2 2013.
  • 8 funds tracked by Wall St. Rank held CARDIUM THERAPEUTICS INC NEW as of Q3 2013.

Based on Shufro Rose & Co's 13F filing for Q3 2013, filed 12 Nov 2013.